Pfizer Inc (PFE) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Pfizer Inc  (NYSE: PFE)
 

Pfizer Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PFE Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) -0.43 % 14.14 % 10.18 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 10.3 % -1.07 % -2.46 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 1.34 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) -0.11 % 2.69 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 8.35 % 7.52 % 8.67 % 13.63 %


PFE's Growth Comparisons in III. Quarter 2026




Although the Major Pharmaceutical Preparations industry saw advancing Revenue by 14.14%, Pfizer Inc announced -0.43% year on year sales decline in the third quarter 2026, to $ 16.58 billions, and underperformed the 10.18% Revenue improvement in the Healthcare sector. Comparing the third quarter, sales Pfizer Inc was trailing overall market not just Major Pharmaceutical Preparations industry.

Top-line improved by 10.3% from the second quarter. Looking into annual sales rise of 8.35%, and S & P 500's average yearly sales growth is 13.63% over the five years, including only Businesses with the third quarter 2026 Results. Pfizer Inc grew less than the market.

PFE Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Comirnaty
-
-
Paxlovid
-
-
Government and Government Sponsored Paxlovid and Comirnaty
0 %
-
Other Business Activities
5.86 %
-
Biopharma
5.36 %
-
U S
4.26 %
-
International Developed Markets
7.8 %
-
International Emerging Markets
6.01 %
-
Biopharma U S Commercial Division
1.51 %
-
Biopharma International Commercial Division
7.92 %
-
Biopharma Global Hospital and Biosimilars Division
21.76 %
-
Pfizer CentreOne
5.86 %
-
Total Alliance revenues
10.7 %
-
Royalty
28.57 %
-
Primary Care Biopharma
-2.64 %
-
Primary Care Eliquis Biopharma
12.64 %
-
Primary Care Prevnar Family Biopharma
1.81 %
-
Primary Care Nurtec ODT Vydura Biopharma
42.34 %
-
Primary Care Comirnaty Biopharma
-58.94 %
-
Primary Care Paxlovid Biopharma
-62.12 %
-
Primary Care Abrysvo Biopharma
37.4 %
-
Primary Care FSME-IMMUN TicoVac Biopharma
28.57 %
-
Primary Care All other Primary Care Biopharma
7.39 %
-
Specialty Care Biopharma
12.35 %
-
Specialty Care Vyndaqel family Biopharma
7.81 %
-
Specialty Care Xeljanz Biopharma
40.63 %
-
Specialty Care Zavicefta Outside the U S and Canada Biopharma
11.11 %
-
Specialty Care Enbrel Outside the U S and Canada Biopharma
-1.43 %
-
Specialty Care Octagam Biopharma
38.64 %
-
Specialty Care Genotropin Biopharma
-2.11 %
-
Specialty Care Cibinqo Biopharma
31.03 %
-
Specialty Care All other Specialty Care Biopharma
19.14 %
-
Oncology Biopharma
9.5 %
-
Oncology Ibrance Biopharma
3.17 %
-
Oncology Padcev Biopharma
38.73 %
-
Oncology Xtandi Biopharma
-3.06 %
-
Oncology Lorbrena Biopharma
37.39 %
-
Oncology Inlyta Biopharma
-2.28 %
-
Oncology Adcetris Biopharma
-12.84 %
-
Oncology Braftovi Mektovi Biopharma
27.94 %
-
Oncology Bosulif Biopharma
-14.57 %
-
Oncology Tukysa Biopharma
19.61 %
-
Oncology Orgovyx Biopharma
43.42 %
-
Oncology Elrexfio Biopharma
33.33 %
-
Oncology Talzenna Biopharma
25 %
-
Oncology Tivdak Biopharma
0 %
-
Oncology All other Oncology Biopharma
-0.27 %
-
Hospital and Biosimilars Biopharma
13.12 %
-
Hospital and Biosimilars Oncology Biosimilars Biopharma
54.92 %
-
Hospital and Biosimilars Sulperazon Outside the U S and Canada Biopharma
21.34 %
-
Hospital and Biosimilars Inflectra Biopharma
18.95 %
-
Hospital and Biosimilars Zithromax Biopharma
-29.11 %
-
Hospital and Biosimilars All Other Hospital and Biosimilars Biopharma
5.77 %
-
Total
5.37 %
-


Growth Rates of PFE's Income in the third quarter 2026


PFE Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - 4.19 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) - -23.95 % -12.21 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) -52.31 % 30.85 % 30.98 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) -41.95 % -2.24 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change 14.19 % 14.12 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) -8.42 % -16.85 % -38.86 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) - -26.31 % -63.27 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) -58.57 % 6.33 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) -6.84 % -9.97 % -4.67 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 2.09 % 14.58 % 8.91 % -28.64 %

PFE Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) -8.68 % -17.47 % -39.2 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) - 21.94 % 11.78 % 27.07 %
Y / Y Net Income Change (Q3 TTM) -58.84 % 5.05 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) -7.05 % -10.2 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth -4.14 % 14.16 % 9.09 % 23.95 %

PFE's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) -8.06 % -31.09 % -38.86 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) - -35.27 % -63.27 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) -58.14 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) -6.49 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 2.86 % -0.46 % 8.91 % -28.64 %



PFE EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) -9.68 % -31.6 % -39.2 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) - 7.1 % 11.78 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) -7.87 % 0.05 % 10.63 % 4.93 %
EPS Net 5 Year Avg. Change -3.56 % 14.16 % 9.09 % 23.95 %



Facing -9.68% year on year income per share decrease in the third quarter, to $ 0.56, Pfizer Inc reported smaller declines than the Major Pharmaceutical Preparations industry with -31.6%, and less than -39.2% slide in the Healthcare sector. Slow third quarter 2026 income per share in Major Pharmaceutical Preparations industry and Healthcare sector, were portrayed in Pfizer Inc's results, which underperformed overall market.

The bottom-line improved by 10.3% from the second quarter. Looking into annual income per share rise of -3.56%, and S & P 500's average yearly income per share growth is 23.95% over the five years, including only Businesses with the third quarter 2026 earnings reports. Pfizer Inc grew less than the market.

PFE Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) 20.02 % 26.04 % 44.26 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) 1490.07 % -29.98 % -42.65 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) 13.59 % 12.35 % 19.33 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) 7.29 % 3.58 % 5.88 % 15.75 %
Free Cash Flow 5 Year Avg. Change -4.81 % 0.88 % 0.41 % 1.8 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) 51.65 % - - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change -28.14 % 29.88 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -4.82 % 18.43 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) 7.5 % -21.14 % -19.32 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) -11.63 % 15.45 % 9.34 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) -1.2 % 1.84 % 0.99 % 23.05 %
Capital Expenditures 5 Year Avg. Change -1.19 % 7.88 % 8.63 % 14.2 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.